Fountain Life Reports Measurable Disease Reversal Using AI-Driven Health Data

Fountain Life announced in a press release new outcomes demonstrating measurable disease reversal across cardiovascular, metabolic, liver, brain, and cancer health categories. The company said these results are backed by over 15 billion clinical data points collected from more than 8,000 members through its AI-powered platform, ZORI.

Fountain Life’s data-driven approach continuously tracks members' health using advanced imaging, blood testing, genetic analysis, and cognitive assessments. This allows clinicians to detect early signs of disease and evaluate whether interventions are producing measurable improvements. According to the company, 26% of members with coronary plaque halted disease progression, while 6% showed plaque regression. Among those with prediabetes, 51% returned to normal blood sugar levels within about a year.

The company also reported that 52% of fatty liver cases resolved, and nearly half of members with accelerated brain aging showed measurable cognitive improvements. Early cancer signals were identified in up to 3.4% of members, often years before conventional screening methods.

Founded in 2020, Fountain Life operates a preventive health model combining AI-guided diagnostics and restorative therapeutics. Its ZORI platform analyzes longitudinal health data to help clinicians identify disease risk earlier and personalize care strategies.